Rationale and design of the randomised controlled cross-over trial: Cardiovascular effects of empaglifozin in diabetes mellitus.

Sharmaine ThirunavukarasuLouise Ae BrownAmrit ChowdharyNicholas JexPeter SwobodaJohn P GreenwoodSven PleinEylem Levelt

Published in: Diabetes & vascular disease research (2021)

This study has full research ethics committee approval (REC: 18/YH/0190) and data collection is anticipated to finish in December 2021. This study was retrospectively registered at https://doi.org/10.1186/ISRCTN82391603 and monitored by the University of Leeds. The study results will be submitted for publication within 6 months of completion.

Keyphrases

study protocol
clinical trial
randomized controlled trial
machine learning
artificial intelligence
phase iii
open label
double blind